New Fiber Probe Enables Real-Time Monitoring of Key Biomarkers for Advanced Health Diagnostics

Researchers have developed a compact mid-infrared optical fiber probe capable of real-time, simultaneous monitoring of three key biomarkers—ethanol, glucose, and lactate—in living tissue.

The probe, described in a study published in Nature Communications, measures just 1.1 millimeters in outer diameter, making it the smallest mid-infrared transflection optical fiber probe reported to date. It consists of two silver halide fibers—one with an angled tip and one gold-coated to act as a mirror—encased in polyetheretherketone tubing and surrounded by a semi-permeable membrane.

When coupled with a quantum cascade laser, the device achieves detection limits of approximately 1 millimolar for each of the three compounds. Researchers used peak deconvolution techniques to resolve overlapping spectral signatures, allowing accurate quantification of ethanol, glucose, and lactate even when present in mixtures.

Validation studies were conducted using ex vivo human skin tissue, with results compared against microdialysis, a established method for sampling interstitial fluid. The probe successfully tracked concentration changes of all three biomarkers in the skin, demonstrating its potential for in vivo applications.

The ability to monitor ethanol, glucose, and lactate simultaneously is significant for biomedical research and clinical care. These metabolites are critical indicators in conditions such as traumatic brain injury, where alcohol levels may influence outcomes, glucose dysregulation affects recovery, and lactate serves as a marker of tissue hypoxia and metabolic stress.

Current methods for tracking multiple biomarkers often require separate sensors or invasive sampling, limiting their use in continuous, real-time monitoring. This integrated probe offers a minimally invasive alternative that could improve precision in critical care settings, particularly for patients with complex metabolic needs.

The research team, affiliated with The University of Texas at Austin, has filed a provisional patent application related to the probe’s design. No further details about clinical trials or timelines for human use were provided in the available sources.